leisure time -WSS

leisure time

author：Wikipedia 2025-09-06 03:55:17 - browse：62852

In a lab at Harvard Medical School, Professor David A. Sinclair looks into the camera from behind a row of bottles — coverage from STAT — David Sinclair in his lab at Harvard Medical School. Craig F. Walker/Globe Staff

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say. But he told his 438,000 followers on X where they could buy it: the website of Animal Bioscience, a veterinary supplement company he founded and which is headed by his brother, Nick Sinclair.

The claim in a company news release, followed by the tweet stating that the supplement was “proven to slow the effects of aging,” has sparked outrage from other scientists online, and the board of an international organization of top longevity researchers — which David Sinclair leads — will discuss the matter at its meeting this week.

Despite his enthusiasm, there is no published scientific research that has yet demonstrated the compounds in Animal Bioscience’s supplements — which have been on the market for more than a year — reverse or even slow aging in dogs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medicare inequities exacerbate Puerto Rico’s health disparities

knowledge

explore

WSS

Medicare inequities exacerbate Puerto Rico’s health disparities

Senate panel eyes new effort on drug shortages

Obesity drugs seen as possible treatment for liver disease MASH

A new nitrogen execution bill also undermines medical licensing

AI can decode, harness the power of the humane immune system

STAT readers on older presidents, polypills, Medicare, and more

focus

leisure time

focus

New air purifier tech could be key to improving indoor air quality

AI can decode, harness the power of the humane immune system

Moonlake's readout produced a cash windfall. Risks remain

R1 RCM gets $5.8 billion buyout offer from private equity firm

New air purifier tech could be key to improving indoor air quality

Liquid biopsy for lung cancer is launched by Delfi

How to save PrEP access — and even expand it

Alabama frozen embryo ruling has major implications for IVF clinics

Apple is now the first public company to be valued at $3 trillion

Why Charlie Gard's case is so disturbing to Americans

explore

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Why palliative psychiatry is worth discussing

Alabama IVF ruling threatens families facing fatal genetic disease

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

New documents shed light on MD Anderson Cancer Institute feud

Bill would stop addiction treatment from triggering child abuse inquiry

hotspot

knowledge

explore

leisure time